AzTrials
AzTrials

Ankle InjuriesPhase 3NCT01945034

5% Topical Ibuprofen (IBU) for Ankle Sprain

A Phase 3 study testing Topical IBU twice daily and Topical IBU three times daily in people with Ankle Injuries, run by Pfizer at 19 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated. Read more about this study

Who is it for?
Ages 12 years and older
Conditions the study is for
Ankle Injuries
What is being tested?
Topical IBU twice daily and Topical IBU three times daily
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
304 participants
Where
19 sitesUnited States
Study dates
Nov 2013to Feb 2015
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • First or second degree ankle sprain within 48 hours of first dose of study medication
  • Medically cleared to participate

Who cannot join

  • Similar injury of same joint within last 6 months
  • Requires bed rest, surgery, or over-the-counter or prescription analgesics

Trial locations and contacts

19 sites in 1 country.

19 sites in 1 country

United States19 sites
  • Orange County Research Institute

    Anaheim, California, 92801

  • Elite Clinical Trials LLLP

    Blackfoot, Idaho, 83221

  • Danville Orthopedic Clinic

    Danville, Virginia, 24541

  • Lillestol Research, LLC

    Fargo, North Dakota, 58103

  • Clinical Trial Network

    Houston, Texas, 77074

  • MedPharmics, LLC

    Metairie, Louisiana, 70006

  • Sunrise Research Institute, Inc.

    Miami, Florida, 33130

  • L&L Research Choices

    Miami, Florida, 33144

  • Quality Clinical Research, Inc.

    Omaha, Nebraska, 68114

  • Heartland Clinical Research, Inc.

    Omaha, Nebraska, 68134

  • PMG Research of Salisbury

    Salisbury, North Carolina, 28144

  • Clinical Trials of Texas, Inc.

    San Antonio, Texas, 78229

  • Clinical Trials of Texas

    San Antonio, Texas, 78229

  • Sports Medicine Associates of San Antonio

    San Antonio, Texas, 78240

  • eStudy Site

    San Diego, California, 92120

  • San Diego Sports Medicine and Family Health Center

    San Diego, California, 92120

  • Helen Keller Hospital

    Sheffield, Alabama, 35660

  • Doctors Research Network

    South Miami, Florida, 33143

  • Visions Clinical Research - Tucson

    Tucson, Arizona, 85712

Other trials in United States

About this study

Official title: Placebo-controlled, Double-blind Evaluation Of The Efficacy And Safety Of Ibuprofen 5% Topical Gel For The Treatment Of Ankle Sprain

This study is being conducted to evaluate the effects of IBU 5% Topical Gel versus topical placebo for the relief of pain associated with a first or second degree ankle sprain. Both twice daily and three times daily regimens will be evaluated.

Conditions
Ankle Injuries
Being tested
Topical IBU twice daily, Placebo twice daily, Topical IBU three times daily, Placebo three times daily
Keywords
topical ibuprofen, ankle sprain
Medical subject headings
Ankle Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Topical IBU twice dailyDrug

    Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days

  • Placebo twice dailyDrug

    Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days

  • Topical IBU three times dailyDrug

    Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days

  • Placebo three times dailyDrug

    Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days

Study groups in NCT01945034
Study groupRoleWhat they receive
Topical IBU twice dailyExperimentalNot described
Receives: Drug: Topical IBU twice daily
Placebo twice dailyPlacebo comparatorNot described
Receives: Drug: Placebo twice daily
Topical IBU three times dailyExperimentalNot described
Receives: Drug: Topical IBU three times daily
Placebo three times dailyPlacebo comparatorNot described
Receives: Drug: Placebo three times daily

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3)

    PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. Pain intensity difference (PID) was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 3 days (72 hours). Total score ranges from -360 (higher pain relief) to 432 (lower pain relief) for SPID WB0-3. SPID is a value of change from baseline and as pain score at base line is usually higher than that at post baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: Over 3 Days (0-72 hours)

  2. Sum of Ankle Pain Intensity Difference on Weight Bearing Over 24 Hours After Dose 1 (SPID WB24)

    PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 24 hours. Total score ranges from -120 (higher pain relief) to 144 (lower pain relief) for SPID WB24. SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while a positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: 0 to 24 hours

Secondary outcomes (13)
  1. Sum of Pain Intensity Difference at Rest Over 24 Hours on Day 1 (SPID R24)

    PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 24 hours. Total score ranges from -240 (higher pain relief) to 96 (lower pain relief) for SPID at rest. SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: 0 to 24 hours

  2. Change From Baseline in Participant's Global Assessment of Ankle Injury at Day 3 and 10

    Participant's global assessments of ankle injury was measured using 5-point scale: 1= Very Good (No symptoms and no limitations of normal activities), 2= Good (Mild symptoms and no limitation of normal activities), 3= Fair (Moderate symptoms and limitations of some normal activities), 4= Poor (Severe symptoms and inability to carry out most normal activities), 5= Very Poor (Very severe symptoms which are intolerable and inability to carry out all normal activities).

    Measured: Baseline, Day 3, 10

  3. Change From Baseline in Physician Global Assessment of Ankle Injury at Day 3 and 10

    The physician assessment of the severity of the ankle injury was based on the participant's individual signs and symptoms which included pain, swelling, tenderness and limitation of range of movement, and was measured using 6-point scale: 0= Normal (No signs or symptoms) , 1= Very mild (Very mild signs and symptoms), 2= Mild (Mild signs and symptoms), 3= Moderate (Moderate signs and symptoms), 4= Severe (Severe signs and symptoms), 5= Very severe (Very severe signs and symptoms). A higher score is indicative of lesser improvement. Change from baseline was calculated as baseline value minus post-treatment value.

    Measured: Baseline, Day 3, 10

  4. Change From Baseline in Ankle Pain at Rest and Upon Weight Bearing (PID NRS) at Pre-specified Time Points

    PI in ankle pain at rest and upon weight bearing was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. Pain score at baseline is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline.

    Measured: Baseline, 1, 2, 3, 4, 5, 6, 12(Day1),24(Day2),30(Day2),36(Day2),48(Day3),50(Day3),54(Day3),60(Day3),72(Day4),78(Day4),84(Day4), 96(Day5),102(Day5), 108 (Day5), 120(Day6),126(Day6),132(Day6),144(Day7),150(Day7),156(Day7) hours post first dose on Day 1

  5. Sum of Pain Intensity Difference at Rest and on Weight Bearing Over 6 Hours on Day 1 and Over 2 Hours on Day 3

    PI at rest and on weight bearing was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID 0-6 was calculated as the time-weighted sum of PID scores over 6 hours on Day 1, with a total score ranges from -30 (higher pain relief) to 36 (lower pain relief). SPID 0-12 was calculated as the time weighted sum of PID scores over 2 hours on Day 3, with a total score ranges from -10 (higher pain relief) to 12 (lower pain relief). SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: Over 6 hours on Day 1, over 2 hours on Day 3

  6. Sum of Pain Intensity Difference Scores at Rest Over 3 Days

    PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 3 days (72 hours). Total score ranges from -360 (higher pain relief) to 432 (lower pain relief). SPID is a value of change from baseline. Pain score at base line is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: Over 3 Days (0-72 hours)

  7. Sum of Pain Intensity Difference Scores at Rest and on Weight Bearing Over 7 Days

    PI was assessed on an 11-point numerical rating scale from 0=no pain to 10=most severe pain. PID was the difference between baseline PI (prior to the first dose) and current PI at assessment. SPID was calculated as the time-weighted sum of PID scores over 7 days (168 hours). Total score ranges from -840 (higher pain relief) to 1008 (lower pain relief). SPID is a value of change from baseline. Pain score at baseline is usually higher than that at post baseline. So negative value of SPID indicates pain relief from baseline, while positive value means a worst pain comparing to baseline, a negative value of SPID indicates higher pain relief from baseline.

    Measured: Over 7 days (0-168 hours)

  8. Change From Baseline in Participant Assessment of Normal Function and Activity at Day 3 and 10

    Participant assessment of normal function was measured using a 5-point scale: 1= Normal walking/activity and no pain; 2= Normal walking/activity with pain; 3= Mildly restricted walking due to pain and can't resume normal activities; 4= Moderately restricted walking due to pain and can't resume normal activities; 5= Severely restricted walking due to pain and can't resume normal activities. The normal functioning and activity scores for each question range from 1 to 5, with higher scores indicating worsening of normal activity.

    Measured: Baseline, Day 3, 10

  9. Participant's Global Assessment of Medication at End of Study

    Participants Global Assessment of Medication was used to rate the medication as a pain reliever. The responses of participants were recorded using 5-point scale: 1= Very Poor, 2= Poor, 3= Fair, 4= Good, 5= Very Good. The global assessment of medication scores for each question range from 0 to 5, giving a possible score range of 0 - 5, with higher scores indicating medication as a better pain reliever.

    Measured: Day 10

  10. Time to First Perceptible Relief and Meaningful Relief

    Participants evaluated time to first perceptible relief by stopping a stopwatch labelled 'first perceptible relief' at moment participant first began to experience any relief, exact question asked was: "Stop stopwatch when you first begin to feel any pain-relieving effect whatsoever of product; that is, when you first feel a little relief". First perceptible relief was considered confirmed by meaningful relief if participant achieved both "first perceptible" and "meaningful" relief by either pressing second stopwatch or by indicating that his/her "first perceptible" relief was also "meaningful". For "time to meaningful relief," exact question asked was: "Stop this stopwatch when you have meaningful relief; that is, when relief from pain is meaningful to you." Stopwatches were active up to 3 hours after dosing or until stopped by participant, or rescue medication was administered.

    Measured: 0 to 3 hours on Day 1

  11. Time to Rescue Medication After Initial Dose, and After Each Subsequent Dose

    Participants used only acetaminophen at a dose of 500 milligram (mg) every 6 hours product as needed (PRN) as rescue medication during the course of the study. Participants who used acetaminophen were to record its use, and date and time of administration in the participant diary. Time to rescue medication after initial dose, after each subsequent dose, provided that in each dose interval at least 25% of the participants take rescue medication was analyzed using the proportional hazard model with site, treatment group, and baseline categorical ankle pain terms in the model.

    Measured: Post-Dose on Day 1 up to Day 10

  12. Number of Doses of Rescue Medication Used During the First 7 Days of Dosing

    Participants received only acetaminophen 500 mg every 6 hours PRN as rescue medication during the course of the study.

    Measured: Baseline up to Day 7

  13. Percentage of Participants Taking Rescue Medication

    Participants used only acetaminophen at a dose of 500 mg every 6 hours PRN as analgesia or rescue therapy during the course of the study. Participants who used acetaminophen were to record its use, and date and time of administration in the participant diary.

    Measured: Post first dose Day 1 up to Day 10

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2013 (estimated)
  2. Study startNov 2013
  3. Primary completionFeb 2015
  4. Study completionFeb 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
304 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01945034
Sponsor's protocol ID
B3491009
Status last verified
Apr 2016
First submitted
21 Jun 2013
Last updated
26 May 2016
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Topical IBU twice daily and Topical IBU three times daily in people with Ankle Injuries, run by Pfizer at 19 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 May 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 19 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 26 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sum of Pain Intensity Difference (SPID) on Weight Bearing Over 3 Days (SPID WB0-3) (time frame: Over 3 Days (0-72 hours)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in